Influence of Cost in the CRO Selection Process
Applied Clinical Trials
Industry Standard Research
Industry Standard Research (ISR) does a significant amount of research in the area of sponsor/CRO relationships. In the course of conducting this research, ISR developed a unique understanding of the process that sponsors go through to select a CRO and the criteria used to evaluate those invited to bid for a particular piece of work. One common observation from CROs is surprising: cost does not rise to the top of their list of selection drivers. In fact, across all phases of research, cost invariably shows up well down the list, behind therapeutic expertise, quality project managers, and prior relationships. Where does this disconnect come from?
Sponsors were then polled to shed some light on their side of the question. In addition to asking what drives their selection, sponsors were asked to speak about the drivers of non-awards. What causes them to rule out a CRO?
By a substantial margin, high cost is the leading response, lending credence to the notion that sponsors are perhaps more price sensitive in their selection process than they indicate in direct responses. This led to the conclusion that while cost is unlikely to win most bids for a service provider, it can certainly lose a bid.
—Industry Standard Research, www.ISRreports.com.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
